前往化源商城

Nature Communications 2014-01-01

Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers.

Hwan-Woo Park, Haeli Park, Ian A Semple, Insook Jang, Seung-Hyun Ro, Myungjin Kim, Victor A Cazares, Edward L Stuenkel, Jung-Jae Kim, Jeong Sig Kim, Jun Hee Lee

文献索引:Nat. Commun. 5 , 4834, (2014)

全文:HTML全文

摘要

Autophagy deregulation during obesity contributes to the pathogenesis of diverse metabolic disorders. However, without understanding the molecular mechanism of obesity interference in autophagy, development of therapeutic strategies for correcting such defects in obese individuals is challenging. Here we show that a chronic increase of the cytosolic calcium concentration in hepatocytes during obesity and lipotoxicity attenuates autophagic flux by preventing the fusion between autophagosomes and lysosomes. As a pharmacological approach to restore cytosolic calcium homeostasis in vivo, we administered the clinically approved calcium channel blocker verapamil to obese mice. Such treatment successfully increases autophagosome-lysosome fusion in liver, preventing accumulation of protein inclusions and lipid droplets and suppressing inflammation and insulin resistance. As calcium channel blockers have been safely used in clinics for the treatment of hypertension for more than 30 years, our results suggest they may be a safe therapeutic option for restoring autophagic flux and treating metabolic pathologies in obese patients.

相关化合物

结构式 名称/CAS号 全部文献
雷帕霉素 结构式 雷帕霉素
CAS:53123-88-9
伏马毒素 B1 结构式 伏马毒素 B1
CAS:116355-83-0
4',6-二脒基-2-苯基吲哚二盐酸盐 结构式 4',6-二脒基-2-苯基吲哚二盐酸盐
CAS:28718-90-3
L-环丝氨酸 结构式 L-环丝氨酸
CAS:339-72-0
去氧肾上腺素 结构式 去氧肾上腺素
CAS:59-42-7